Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-070827
Filing Date
2025-07-25
Accepted
2025-07-25 16:08:08
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8677
2 EXHIBIT 1 tm2521419d1_ex-1.htm EX-24.1 6385
  Complete submission text file 0001104659-25-070827.txt   17185
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Subject) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-54847 | Film No.: 251151764
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001
Business Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001 212-478-0000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

EIN.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G